Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16681962 | 0.83 | CTSK (0.51) | TAS1R3TAS1R1ACEHPGDTAAR1 | |
| SCHEMBL16681992 | 0.83 | CTSK (0.51) | TAS1R3TAS1R1ACEHPGDTAAR1 | |
| SCHEMBL16670450 | 0.78 | TAS1R3 (0.46) | TAS1R3TAS1R1ACEHPGDTRPA1 | |
| SCHEMBL16670168 | 0.78 | TAS1R3 (0.46) | TAS1R3TAS1R1ACEHPGDTRPA1 | |
| SCHEMBL16670166 | 0.78 | TAS1R3 (0.46) | TAS1R3TAS1R1ACEHPGDTRPA1 | |
| SCHEMBL16671524 | 0.77 | TAS1R3 (0.54) | TAS1R3TAS1R1ACEHPGDLMNA | |
| SCHEMBL10204542 | 0.77 | ACE (0.50) | ACELMNAALDH1A1MAOA | |
| SCHEMBL27010613 | 0.77 | ACE (0.50) | ACELMNAALDH1A1MAOA | |
| SCHEMBL29679318 | 0.77 | ACE (0.50) | ACELMNAALDH1A1MAOA | |
| SCHEMBL14484813 | 0.74 | NPC1 (0.44) | HPGDEDNRANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-20160257645-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2016-09-08 | — | — | US | disclosed |
| US-20160257645-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257645-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR1E, POLR1G | TAS1R3 4744/4885TAS1R1 4622/4885ACE 312/4885 |
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, POLR1G, POLR1E | TAS1R3 4755/4885TAS1R1 4618/4885ACE 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.